Provolol Pharmaceutical (000739.SZ) subsidiary obtained drug registration certificate for levocarnitine oral solution

According to Zhitong Finance App, Prologis Pharmaceutical (000739.SZ) issued an announcement. Zhejiang Prokanyu Pharmaceutical Co., Ltd. (hereinafter referred to as “Kangyu Pharmaceutical”), a holding subsidiary of the company, has received the “Drug Registration Certificate” for the oral solution of levocarnitine issued by the China Drug Administration (hereinafter referred to as the “Drug Administration”). Levocarnitine oral solution is used to treat primary systemic carnitine deficiency, as well as short- and long-term treatment of secondary carnitine deficiency due to congenital metabolic abnormalities.